RESULTS
Test‐Revised, Depression
DISORDER, DISORDERS
Data collection started on 11 March 2019 and concluded on 16 June 2021 when 48 participants (After weight adjustment by participants' actual weight, adolescents received a mean THC dose of 6.8 mg (SD = 0.9; range = 5.4–8.7 mg), and adults received a mean THC dose of 7.4 mg (SD = 1.4; range = 5.4–10.7 mg) on both ‘THC’ and ‘THC + CBD’ conditions. On ‘THC + CBD’ adolescents received a mean CBD dose of 20.3 mg (SD = 2.6; range = 16.3–26.1 mg), and adults received a mean CBD dose of 22.2 mg (SD = 4.3; range = 16.3–32.2 mg) of CBD. These differences were not statistically significant (THC: For a summary of participant characteristics, see Table Summary of participants' baseline sociodemographic characteristics and drug use
Abbreviations = AUDIT, Alcohol Use Disorders Identification Test; BDI = Beck Depression Inventory; CUDIT‐R = Cannabis Use disorder Identification Test‐Revised; SES = socio‐economic status; s‐UPPS‐P = Short Urgency‐Premeditation‐Perseverance‐Sensation Seeking‐Positive Urgency.
Pre‐drug administration (T1) minimal THC was detected in plasma. Across the three conditions, four participants had a plasma THC level >0.5 ng/mL; all other participants had plasma THC levels that were zero. The non‐zero levels were all <1.25 ng/mL. Pre‐drug administration, at T1, across the three conditions, all participants had a zero plasma CBD level (Table 